euro adhoc: Marseille-Kliniken AG / Financial Figures/Balance Sheet / - Increase in turnover in the financial year 2007/2008 to EUR 228.1 m - Consolidated net income reaches EUR 1.14 per share - Sur

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

annual report

31.10.2008

Berlin, 31 October 2008. Marseille-Kliniken AG (Prime Standard, ISIN
DE 0007783003, MKA) was able to accelerate its growth in the
financial year and considerably increase its results against the
previous period. Consolidated turnover in the financial year
2007/2008 increased to EUR 228.1 m (previous year: EUR 214.8 m). The
annual surplus after minority interest improved from EUR 9.1 m to EUR
13.8 m. This considerable increase in the unadjusted result can be
mainly attributed to extraordinary gains from another
sale-and-lease-back transaction as well as income from the adjustment
of deferred taxes in the run-up to the German corporation tax reform
2008. This amounts to earnings per share of EUR 1.14 compared to EUR
0.75 in the previous year.

EBIT include other taxes reached EUR 22,1 m against EUR 23.3 m in the
previous year. EBITDAR reached EUR 73.8 m and was above previous year
levels (EUR 69.6 m). Equity amounted to EUR 84.0 m compared to EUR
71.2 m in the previous year, corresponding to an equity ratio of
35.1% (previous year: 23.0%).

Earnings according to DVFA/SG (IFRS) reached EUR 11.2 m in the
financial year compared to EUR 10.5 m in the previous year. This
amounts to EUR 0.93 per share (previous year: EUR 0.86). EBITDAR
increased slightly against the previous year from EUR 61.8 m to EUR
62.6 m. EBIT fell to EUR 17.5 m (previous year: EUR 20.2 m).

At the end of the financial year the Care segment reached a capacity
of 7,616 beds (previous year: 7,287 beds) in 56 institutions. In the
period under review turnover increased from EUR 166.5 m to EUR 176.4
m. Earnings according to DVFA fell from EUR 12.7 m in the previous
year to EUR 7.2 m Soft results in Care segment can be mainly
attributed to a significant increase in energy costs due to adverse
weather conditions as well as the development of food prices. In
addition to that, the company made a one-off pre-payment of EUR 1.5 m
for the comprehensive implementation of an eLearning platform for
groupwide quality management for 2800 employees. Occupancy levels in
Care were continually increased against the market trend and reached
an average value of 93.3% compared to 92.8% in the previous year. At
group level occupancy was also increased and reached 92.4% at a
capacity of 8,899 beds compared to 89.7% in the previous year.

The Rehabilitation segment was again able to increase its positive
contribution to turnover and profits at group level, despite further
reducing bed capacity. Bed capacity dropped from 1,478 in the
previous year to its current total of 1,283 beds in nine
institutions. Occupancy was again considerably optimized and
increased from 75.9% in the previous year to 90.4% in the full year.
Turnover in Rehabilitation improved from EUR 48.3 m in the previous
year to EUR 51.7 m in the period under review. The result according
to DVFA/SG (IFRS) reached EUR 4.0 m marking a significant leap into
profitability (previous year: EUR -2.2 m).

In the current financial year capacities are being expanded further.
The company already opened a new facility in Meerbusch back in July.
More Care facilities are planned for Oberhausen and Waldkirch. The
company is confident that the 2-Star concept has significant growth
potential and it is therefore being applied consistently. Market
analysis for suitable locations and facilities for the concept has
been completed. The company is expecting to be implementing 3,000
residential units in the next three years, which would then increase
total capacity to 12,000 beds.

For the current and the following financial year the company is
expecting growth of at least 6.5% annually. Turnover and earnings are
going to be positively impacted by the continual increase in
occupancy, especially in the facilities involved in the expansion
plans. The company is expecting an EBIT return of at least 7% in the
financial year 2008/2009.

The annual report for the business year 2007/2008 will be published
today at the company´s homepage www.marseille-kliniken.com. The
results for the first quarter of the current business year 2008/2009
will be announced on 10. November.

End of ad hoc release

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Marseille-Kliniken AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Marseille-Kliniken AG

Axel Hölzer

CEO

Alte Jakobstraße 79/80

10709 Berlin

Germany

Tel.: +49 30 / 246 32-400

Fax: +49 30 / 246 32-401

www.marseille-kliniken.com

Hillermann Consulting

Christian Hillermann

Investor Relations Marseille-Kliniken AG

Poststraße 14/16

20354 Hamburg

Germany

Tel.: +49 40 / 320 279 10

Fax: +49 40 / 320 279 114

www.hillermann-consulting.de

Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hamburg / regulated dealing